The COMBINE Study evaluated the effects of acamprosate, naltrexone and the Combined Behavioral Intervention (CBI). In secondary analyses, our goals were to identify trajectories of any drinking prior to randomization, to characterize subjects in these trajectories, and to assess whether pre-randomization trajectories predict drinking outcomes and moderate treatment response
The opioid receptor antagonist naltrexone (NTX) reduces goal-directed alcohol drinking in rats presu...
BackgroundOral naltrexone is an efficacious medication for treatment of alcohol dependence, but smal...
Naltrexone and acamprosate both modestly curtail drinking among alcohol-dependent patients, but whic...
The COMBINE Study evaluated the effects of acamprosate, naltrexone and the Combined Behavioral Inter...
The COMBINE Study sought to answer questions about the benefits of combining behavioral and pharmaco...
Objective—COMBINE is the largest study of pharmacotherapy for alcoholism in the United States to dat...
1. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBIN...
The investigators of the COMBINE (Combining Medications and Behavioral Interventions for Alcoholism)...
These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given t...
These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given t...
BACKGROUND: In a recent study conducted in a family medicine setting, the medication acamprosate was...
Aim: To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the t...
Within the alcoholism field, there is mounting evidence supporting an important relationship between...
Naltrexone can help prevent relapse in recently detoxified patients with alcohol use disorder. The e...
Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone ...
The opioid receptor antagonist naltrexone (NTX) reduces goal-directed alcohol drinking in rats presu...
BackgroundOral naltrexone is an efficacious medication for treatment of alcohol dependence, but smal...
Naltrexone and acamprosate both modestly curtail drinking among alcohol-dependent patients, but whic...
The COMBINE Study evaluated the effects of acamprosate, naltrexone and the Combined Behavioral Inter...
The COMBINE Study sought to answer questions about the benefits of combining behavioral and pharmaco...
Objective—COMBINE is the largest study of pharmacotherapy for alcoholism in the United States to dat...
1. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBIN...
The investigators of the COMBINE (Combining Medications and Behavioral Interventions for Alcoholism)...
These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given t...
These analyses of the COMBINE Study examined the effects of naltrexone among non-abstainers. Given t...
BACKGROUND: In a recent study conducted in a family medicine setting, the medication acamprosate was...
Aim: To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the t...
Within the alcoholism field, there is mounting evidence supporting an important relationship between...
Naltrexone can help prevent relapse in recently detoxified patients with alcohol use disorder. The e...
Aims: To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone ...
The opioid receptor antagonist naltrexone (NTX) reduces goal-directed alcohol drinking in rats presu...
BackgroundOral naltrexone is an efficacious medication for treatment of alcohol dependence, but smal...
Naltrexone and acamprosate both modestly curtail drinking among alcohol-dependent patients, but whic...